secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001437749-25-021093
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex reports positive preclinical data for diabetes gene therapy GPX-002 at ADA
--------------------------------------------------------------------------------

- Alpha cells in Type 1 diabetes mouse models transdifferentiated to insulin-secreting beta-like cells after GPX-002 infusion.
- In diabetic non-human primates, GPX-002 improved glucose tolerance and reduced insulin requirements at one month post-infusion.
- Three-month immunosuppression with rituximab, rapamycin, and steroids largely prevented anti-viral immunity in NHPs.
- Continued studies will evaluate GPX-002 efficacy after six months of immunosuppression in NHP models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925021093/0001437749-25-021093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925021093/gnpx20250618c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-021093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer